Serina Therapeutics
27 hedge funds and large institutions have $2.73M invested in Serina Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
8% more funds holding
Funds holding: 25 → 27 (+2)
4% less capital invested
Capital invested by funds: $2.86M → $2.73M (-$128K)
2.58% less ownership
Funds ownership: 11.96% → 9.38% (-2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$39K |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$5.75K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.24K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.52K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$105K |
| 2 |
Jane Street
New York
|
-$45.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$26.2K |
| 4 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$714 |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
-$447 |
SER Hedge Fund Activity: Q2 2026 in Review
27 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q2 2026, worth a combined $2.73M — down 4.5% from $2.86M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SER positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $39K. The largest seller was BlackRock, cutting an estimated $105K.
- 27 institutional investors held Serina Therapeutics (SER) as of Q2 2026, up from 25 in Q1 2026.
- Funds reported $2.73M of Serina Therapeutics stock for Q2 2026, down 4.5% quarter-over-quarter.
- 5 funds opened new Serina Therapeutics positions in Q2 2026 and 3 closed out, a net change of +2 holders.
- The largest Serina Therapeutics buyer in Q2 2026 was Northern Trust, an estimated $39K added.
- The largest Serina Therapeutics seller in Q2 2026 was BlackRock, an estimated $105K sold.
Based on aggregated 13F filings for Q2 2026.